1. Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China; 2. Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
Abstract：Interferon α (IFNα) therapy remains a mainstay of treatment of chronic hepatitis B. However, sustained remission rates remain relatively low, and the search for factors important for response to therapy continues. In order to study the relationship between the genomic DNA methylation profile and response to interferon therapy in chronic hepatitis B, pretreatment plasma samples of 20 patients with chronic hepatitis B (CHB) receiving pegylated interferon α (PEGIFNα) treatment were subjected to DNA methylation analyses using RocheNimbleGen Human DNA Methylation 2.1M Deluxe Promoter v2 Array. Methylated DNA immunoprecipitationquantitative polymerase chain reaction (MeDIPqPCR) was used to further validate the methylation status of specific genes. A total of 588 genes were found to show differential methylation in interferon nonresponse group as compared with the rapid response group. These differential methylated genes were involved in several signaling pathways, such as the calcium signaling pathway, cell cycle and liver metabolism. The methylation levels of several genes in the two groups were confirmed by MeDIPqPCR, consistent with the results of the MeDIPchip study. Our data provide a foundation for future study on the functions of differential methylated genes in interferon response as well as the discovery of new molecular markers for predicting prognosis of interferon therapy in CHB patients.
邬敏1，张小楠1，陈捷亮2，袁正宏1’2. 不同干扰素应答慢性乙型肝炎患者的基因组DNA甲基化谱差异分析[J]. 微生物与感染, 2014, 9(4): 217-223.
WU Min1, ZHANG Xiao-nan1, CHEN Jie-liang2, YUAN Zheng-hong2. Differential analysis of DNA methylation profile between responder and nonresponder of interferon treatment in chronic hepatitis B patients. JOURNAL OF MICROBES AND INFECTIONS, 2014, 9(4): 217-223.
